Shuhei Nishiyama
Overview
Explore the profile of Shuhei Nishiyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1025
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamazaki N, Misu T, Matsumoto Y, Takai Y, Namatame C, Ono H, et al.
Mult Scler Relat Disord
. 2024 Nov;
92:106176.
PMID: 39579645
Background: Neuromyelitis optica spectrum disorder (NMOSD), a central nervous system inflammatory disease associated with aquaporin-4 immunoglobulin G (AQP4-IgG), is conventionally treated with oral steroids and immunosuppressants (IS) in Japan. Several...
2.
Drosu N, Anderson M, Bilodeau P, Nishiyama S, Mikami T, Bobrowski-Khoury N, et al.
Proc Natl Acad Sci U S A
. 2024 Oct;
121(44):e2416097121.
PMID: 39432795
Both genetic and environmental factors contribute to multiple sclerosis (MS) risk. Infection with the Epstein-Barr virus (EBV) is the strongest environmental risk factor, and HLA-DR15 is the strongest genetic risk...
3.
Wright A, Nishiyama S, Han P, Kong P, Levy M
BMC Neurosci
. 2024 Mar;
25(1):16.
PMID: 38468222
Background: Myelin oligodendrocyte glycoprotein-associated disorders (MOGAD) is an autoimmune central nervous system disease. Antigen-specific immune tolerance using nanoparticles such as Polylactic-co-glycolic acid (PLGA) have recently been used as a new...
4.
Nishiyama S, Seok J, Wright A, Lotan I, Mikami T, Drosu N, et al.
Sci Rep
. 2024 Feb;
14(1):3146.
PMID: 38326464
Proinflammatory cytokines, such as (IL: interleukin) IL-6 and IL-17A, and complement fixation are critical in the immunopathogenesis of neuromyelitis optica spectrum disorders (NMOSD). Blocking the IL-6 receptor or the C5...
5.
Srivastava P, Nishiyama S, Zhou F, Lin S, Srivastava A, Su C, et al.
J Neuroimmune Pharmacol
. 2023 Dec;
18(4):704-717.
PMID: 38110615
Background: Melanocortin 1 receptor (MC1R) is a key pigmentation gene, and loss-of-function of MC1R variants that produce red hair may be associated with Parkinson's disease (PD). We previously reported compromised...
6.
Molazadeh N, Akaishi T, Bose G, Nishiyama S, Chitnis T, Levy M
Mult Scler Relat Disord
. 2023 Nov;
80:105093.
PMID: 37949025
Objectives: To determine whether progression independent of relapse activity (PIRA) is present in Aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD), Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and relapsing remitting Multiple sclerosis...
7.
Srivastava P, Nishiyama S, Lin S, Srivastava A, Su C, Peng W, et al.
Res Sq
. 2023 Jul;
PMID: 37398302
Background: Melanocortin 1 receptor () is a key pigmentation gene, and loss-of-function of variants that produce red hair may be associated with Parkinson's disease (PD). We previously reported compromised dopaminergic...
8.
Lotan I, Nishiyama S, Wright A, Seok J, Levy M
Neuroscience
. 2023 Jun;
524:89-93.
PMID: 37290683
Experimental autoimmune encephalomyelitis (EAE) is an animal model of Inflammatory central nervous system (CNS) disease. Dark agouti (DA) rats immunized with full-length myelin oligodendrocyte glycoprotein (MOG) typically develop a relapsing-remitting...
9.
Akaishi T, Misu T, Fujihara K, Nakaya K, Nakaya N, Nakamura T, et al.
Sci Rep
. 2023 Apr;
13(1):6481.
PMID: 37081126
White blood cell (WBC) count profiles in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are still unknown. This study evaluated the total WBC...
10.
Nishiyama S, Wright A, Lotan I, Mikami T, Paul F, Aoki M, et al.
J Neuroinflammation
. 2022 Dec;
19(1):296.
PMID: 36503481
Background And Objectives: Inhibition of terminal complement in neuromyelitis optica spectrum disorder (NMOSD) using eculizumab helps prevent relapses, but the exact mechanism of action of the drug remains unclear. Similarly,...